Merck buys Schering-Plough: first thoughts

So after weeks of rumors, Merck has decided to buy Schering-Plough. This ends two eras - the one where S-P was one of the last mid-sized pharmaceutical companies, and the one where Merck grew mostly from the inside. I have to say, I'm sorry to see the end of both. Drug discovery is risky and complicated, and it needs as many different viewpoints and shots on goal as possible. Big mergers like this don't help the industry's ecology much. Today's merger isn't as disturbing as the Blob-like growth of Pfizer, but it's still not happy news. (Full disclosure: I used to work at Schering-Plough in the 1990s - a few tales from that era can be found here and here).

Does this deal make sense?


If you think that big drug company mergers make sense, then I suppose it does. The two companies have Vytorin, the combination cholesterol drug that's not going to be make anyone as much money as it was supposed to. And Schering-Plough has a promising cardiovascular drug and some other programs that will fit reasonably well into Merck's portfolio. The two main R&D sites are within a few miles of each other in New Jersey, so it'll be interesting to see how the staffing and facilities issues eventually get resolved (there are supposed to be cost savings in that area, naturally).

I'm still not happy about this one, but I'm clearly out of step. I miss the days when large drug companies could keep themselves going with their own research programs. I worry about the vitality of research under the present conditions. And I wonder what happens when there aren't any more big mergers to be made.

Derek Lowe blogs from inside the drug labs at In the Pipeline.

Presented by

Derek Lowe

Derek Lowe is a drug discovery chemist with 20 years of experience in the pharmaceutical industry, which is still very much his day job. He's worked on projects targeted at Alzheimer's, cancer, diabetes, infectious diseases, and other areas, but like most discovery scientists in the business, he has yet to produce a marketed drug. Explaining how and why this happens is what led to the launch of his blog, "In the Pipeline", in 2002, and the explaining continues. . .

Never Tell People How Old They Look

Age discrimination affects us all. Who cares about youth? James Hamblin turns to his colleague Jeffrey Goldberg for advice.

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register.

blog comments powered by Disqus

Video

Never Tell People How Old They Look

Age discrimination affects us all. James Hamblin turns to a colleague for advice.

Video

Would You Live in a Treehouse?

A treehouse can be an ideal office space, vacation rental, and way of reconnecting with your youth.

Video

Pittsburgh: 'Better Than You Thought'

How Steel City became a bikeable, walkable paradise

Video

A Four-Dimensional Tour of Boston

In this groundbreaking video, time moves at multiple speeds within a single frame.

Video

Who Made Pop Music So Repetitive? You Did.

If pop music is too homogenous, that's because listeners want it that way.

More in Business

Just In